急性冠状动脉综合征治疗“金标准”遭遇挑战——GEMINI-ACS-1研究解读
高霏,周玉杰,赵迎新
摘要(Abstract)：
<正>早在1988年发表于柳叶刀杂志的ISIS-2研究[1]揭示,与安慰剂相比,阿司匹林可以使急性冠状动脉综合征(acute coronary syndrome,ACS)患者的心血管死亡下降23%,奠定了阿司匹林在ACS患者治疗方案中不可或缺的"金标准"地位。但随着更强效的血小板抑制药——P2Y12抑制药的出现,ACS患者的治疗迎来新一轮革命,步入了阿司匹林联合P2Y12抑制药的"双联抗血小板治疗"时代。而近年
关键词(KeyWords)： 急性冠状动脉综合征;双联抗血小板治疗
基金项目(Foundation):
作者(Author): 高霏,周玉杰,赵迎新
参考文献(References)：
- [1]Randomised trial of intravenous streptokinase,oral aspirin,both,or neither among 17,187 cases of suspected acute myocardial infarction:ISIS-2.ISIS-2(Second International Study of Infarct Survival)collaborative group.Lancet,1988,2(8607):349-360.
- [2]Wiviott SD,Braunwald E,Mc Cabe CH,et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes.N Engl J Med,2007,357(20):2001-2015.
- [3]Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med,2009,361(11):1045-1057.
- [4]Gurbel PA,Tantry US.Combination antithrombotic therapies.Circulation,2010,121(4):569-583.
- [5]Mega JL,Braunwald E,Wiviott SD,et al.Rivaroxaban in patients with a recent acute coronary syndrome.N Engl J Med,2012,366(1):9-19.
- [6]Ohman EM,Roe MT,Steg PG,et al.Clinically signifi cant bleeding with low-dose rivaroxaban versus aspirin,in addition to P2Y12inhibition,in acute coronary syndromes(GEMINI-ACS-1):a doubleblind,multicentre,randomised trial.Lancet,2017,389(10081):1799-1808.